Vitrobio

À propos

After 17 years of R&D on virus surface glycoproteins, wound MMPs & dermal cytokines, VITRO-BIO Pharma France discovered, patented & recently (2010) obtained EU marketing authorization for the 1st topical anti-viral & MMP inhibitors to treat , Rhinosinusitis , Bedsores & Diabetic ulcers, Throat infection, Labial herpes, Psoriasis, Eczema , Genital herpes & infection, & Oral Mucositis. These new scientific approaches of directly inhibiting Virus surface Gps & wound MMPs were honored with European PAEXA & French Acd. Sci. awards. Vitrobio is purely a R&D company. Patents, publications, clinical reports, & complete dossiers are available for immediate worldwide outlicensing of our products, which can be sold as OTC or Rx. Due to their topical filmogen mode of action, the products are registered as Class I or Class IIa medical devices, and are manufactured in France in compliance with GMP. Partnering strategy/collaborations : Seeking partners having well-established distribution network in pharmacies, OTC and / or hospitals and looking to in-licence innovative drugs. Our products can be sold as OTC or Prescription products. Investors interested in small Pharma companies are welcome to contact us. Since 2011, some of our products have already been outlicensed and launched in 11 countries, while being currently under launch in 9 other countries.